Review Article | Published:

Short-chain fatty acids in control of body weight and insulin sensitivity

Nature Reviews Endocrinology volume 11, pages 577591 (2015) | Download Citation

Abstract

The connection between the gut microbiota and the aetiology of obesity and cardiometabolic disorders is increasingly being recognized by clinicians. Our gut microbiota might affect the cardiometabolic phenotype by fermenting indigestible dietary components and thereby producing short-chain fatty acids (SCFA). These SCFA are not only of importance in gut health and as signalling molecules, but might also enter the systemic circulation and directly affect metabolism or the function of peripheral tissues. In this Review, we discuss the effects of three SCFA (acetate, propionate and butyrate) on energy homeostasis and metabolism, as well as how these SCFA can beneficially modulate adipose tissue, skeletal muscle and liver tissue function. As a result, these SCFA contribute to improved glucose homeostasis and insulin sensitivity. Furthermore, we also summarize the increasing evidence for a potential role of SCFA as metabolic targets to prevent and counteract obesity and its associated disorders in glucose metabolism and insulin resistance. However, most data are derived from animal and in vitro studies, and consequently the importance of SCFA and differential SCFA availability in human energy and substrate metabolism remains to be fully established. Well-controlled human intervention studies investigating the role of SCFA on cardiometabolic health are, therefore, eagerly awaited.

Key points

  • Short-chain fatty acids (SCFA), which are derived from gut microbial fermentation of indigestible foods, have important metabolic functions and are crucial for intestinal health

  • The discovery of SCFA receptors in many different tissues highlights that SCFA are involved in the crosstalk between the gut and peripheral tissues

  • In addition to their role in gut health and as signalling molecules, SCFA might enter the systemic circulation and directly affect substrate metabolism and function of peripheral tissues

  • SCFA might increase intestinal energy harvesting and promote the development of obesity, but could also increase energy expenditure and anorexic hormone production, as well as improving appetite regulation

  • Increasing evidence supports a beneficial role for SCFA in adipose tissue, skeletal muscle and liver substrate metabolism and function, thereby contributing to improved insulin sensitivity

  • Well-controlled human intervention studies investigating the role of SCFA and differential SCFA availability on gut and systemic metabolic health are eagerly awaited

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N. Engl. J. Med. 371, 1131–1141 (2014).

  2. 2.

    Obesity, metabolic syndrome, and cardiovascular disease. J. Clin. Endocrinol. Metab. 89, 2595–2600 (2004).

  3. 3.

    , & Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444, 840–846 (2006).

  4. 4.

    et al. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl Acad. Sci. USA 101, 15718–15723 (2004).

  5. 5.

    et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027–1031 (2006).

  6. 6.

    et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J. 22, 2416–2426 (2008).

  7. 7.

    et al. Probiotics lower plasma glucose in the high-fat fed C57BL/6J mouse. Benef. Microbes 1, 189–196 (2010).

  8. 8.

    et al. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J. Hepatol. 60, 824–831 (2014).

  9. 9.

    et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143, 913–916 (2012).

  10. 10.

    & Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol. Rev. 81, 1031–1064 (2001).

  11. 11.

    et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 156, 84–96 (2014).

  12. 12.

    et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58, 1509–1517 (2009).

  13. 13.

    et al. Butyrate and propionate protect. against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS ONE 7, e35240 (2012).

  14. 14.

    et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat. Commun. 5, 3611 (2014).

  15. 15.

    & Acute effects of intravenous and rectal acetate on glucagon-like peptide-1, peptide YY, ghrelin, adiponectin and tumour necrosis factor-alpha. Br. J. Nutr. 103, 460–466 (2010).

  16. 16.

    et al. Short-chain fatty acids protect against high-fat diet-induced obesity via a PPARγ-dependent switch from lipogenesis to fat oxidation. Diabetes 64, 2398–2408 (2015).

  17. 17.

    et al. Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut 59, 1635–1642 (2010).

  18. 18.

    et al. Propionic acid affects immune status and metabolism in adipose tissue from overweight subjects. Eur. J. Clin. Invest. 42, 357–364 (2012).

  19. 19.

    et al. Regulation of adipokine production in human adipose tissue by propionic acid. Eur. J. Clin. Invest. 40, 401–407 (2010).

  20. 20.

    & Bacteria, colonic fermentation, and gastrointestinal health. J. AOAC Int. 95, 50–60 (2012).

  21. 21.

    , , , & Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28, 1221 (1987).

  22. 22.

    , , & Effects of amino acid-derived luminal metabolites on the colonic epithelium and physiopathological consequences. Amino Acids 33, 547–562 (2007).

  23. 23.

    et al. Influence of dietary protein supplements on the formation of bacterial metabolites in the colon. Gut 41, 70–76 (1997).

  24. 24.

    , , & Estimation of short-chain fatty acid production from protein by human intestinal bacteria based on branched-chain fatty acid measurements. FEMS Microbiol. Lett. 101, 81–88 (1992).

  25. 25.

    et al. Colonic protein fermentation and promotion of colon carcinogenesis by thermolyzed casein. Nutr. Cancer 23, 271–281 (1995).

  26. 26.

    , & Relevance of protein fermentation to gut health. Mol. Nutr. Food Res. 56, 184–196 (2012).

  27. 27.

    , , , & Colonic health: fermentation and short chain fatty acids. J. Clin. Gastroenterol. 40, 235–243 (2006).

  28. 28.

    et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity 18, 190–195 (2009).

  29. 29.

    , , , & Adiposity, gut microbiota and faecal short chain fatty acids are linked in adult humans. Nutr. Diabetes 4, e121 (2014).

  30. 30.

    & Colonic microflora: nutrition and health. Nutrition 13, 476–478 (1997).

  31. 31.

    & In vitro fermentabilities of purified fiber supplements. J. Food Sci. 54, 347–350 (1989).

  32. 32.

    , , & Comparison of ileal effluents, dietary fibers, and whole foods in predicting the physiological importance of colonic fermentation. Am. J. Gastroenterol. 83, 536–540 (1988).

  33. 33.

    Microbial metabolites produced by the colonic microbiota as drivers for immunomodulation in the host. FASEB J. 27, 643.12 (2013).

  34. 34.

    , & Comparison of different fibers for in vitro production of short chain fatty acids by intestinal microflora. J. Med. Food 8, 113–116 (2005).

  35. 35.

    , , & Sex differences in colonic function: a randomised trial. Gut 34, 531–536 (1993).

  36. 36.

    , , & Gastrointestinal effects of sugarbeet fiber and wheat bran in healthy men. Eur. J. Clin. Nutr. 47, 543–548 (1993).

  37. 37.

    & Ruminal microbial yields: factors influencing synthesis and bypass. Fed. Proc. 36, 198–202 (1977).

  38. 38.

    & Increasing butyrate concentration in the distal colon by accelerating intestinal transit. Gut 41, 245–251 (1997).

  39. 39.

    et al. Relationships between transit time in man and in vitro fermentation of dietary fiber by fecal bacteria. Eur. J. Clin. Nutr. 54, 603–609 (2000).

  40. 40.

    , , , & Absorption of short-chain fatty acids by the colon. Gastroenterology 78, 1500–1507 (1980).

  41. 41.

    & Short-chain fatty acid transport in the intestine of a herbivorous teleost. J. Exp. Biol. 135, 77–94 (1988).

  42. 42.

    , , , & Identification and characterization of a monocarboxylate transporter (MCT1) in pig and human colon: its potential to transport L-lactate as well as butyrate. J. Physiol. 513, 719–732 (1998).

  43. 43.

    , , , & Significance of short chain fatty acid transport by members of the monocarboxylate transporter family (MCT). Neurochem. Res. 37, 2562–2568 (2012).

  44. 44.

    et al. Short chain fatty acids exchange across the gut and liver in humans measured at surgery. Clin. Nutr. 28, 657–661 (2009).

  45. 45.

    & in Colorectal Surgery (eds Bailey, H. R., Billingham, R. P., Stamos, M. J. & Snyder, M. J.) 3–17 (Elsevier Health Sciences, 2012).

  46. 46.

    et al. Short chain fatty acids exchange: Is the cirrhotic, dysfunctional liver still able to clear them? Clin. Nutr. 29, 365–369 (2010).

  47. 47.

    , , , & Insulin-sensitizing effects of dietary resistant starch and effects on skeletal muscle and adipose tissue metabolism. Am. J. Clin. Nutr. 82, 559–567 (2005).

  48. 48.

    Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut 21, 793–798 (1980).

  49. 49.

    in Physiological and Clinical Aspects of Short-Chain Fatty Acids (eds Cummings, J. H., Rombeau, J. L. & Sakata, T.) 337–351 (Cambridge University Press, 1995).

  50. 50.

    & Fuel utilization in colonocytes of the rat. Biochem. J. 231, 713–719 (1985).

  51. 51.

    et al. Mediation of the trophic effects of short-chain fatty acids on the rat jejunum and colon. Gastroenterology 106, 375–380 (1994).

  52. 52.

    et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J. Biol. Chem. 278, 11312–11319 (2003).

  53. 53.

    et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J. Biol. Chem. 278, 25481–25489 (2003).

  54. 54.

    et al. Expression of the short-chain fatty acid receptor, GPR43, in the human colon. J. Mol. Histol. 39, 135–142 (2008).

  55. 55.

    et al. Expression of short-chain fatty acid receptor GPR41 in the human colon. Biomed. Res. 30, 149–156 (2009).

  56. 56.

    et al. GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res. 69, 2826–2832 (2009).

  57. 57.

    et al. The expression of GPR109A, NF-κB and IL-1β in peripheral blood leukocytes from patients with type 2 diabetes. Ann. Clin. Lab. Sci. 44, 443–448 (2014).

  58. 58.

    et al. (D)-β-hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J. Biol. Chem. 280, 26649–26652 (2005).

  59. 59.

    et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med. 9, 352–355 (2003).

  60. 60.

    et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc. Natl Acad. Sci. USA 110, 4410–4415 (2013).

  61. 61.

    , & Acetate metabolism in isolated epididymal adipose tissue from obese-hyperglycemic mice of different ages. Acta Physiol. Scand. 56, 189–198 (1962).

  62. 62.

    The effect of insulin on the incorporation of C14-labeled pyruvate and acetate into lipid and protein. Anat. Rec. 101, 680 (1948).

  63. 63.

    Metabolism of adipose tissue. I. Incorporation of acetate carbon into lipides by slices of adipose tissue. J. Biol. Chem. 206, 171–180 (1954).

  64. 64.

    , & Lipid metabolism in the diabetic rat. IV. Metabolism of acetate, acetoacetate, butyrate, and mevalonate in vitro. J. Biol. Chem. 235, 573–577 (1960).

  65. 65.

    & Lipid metabolism in the diabetic rat. I. Acetate metabolism and lipid synthesis in vivo. J. Biol. Chem. 235, 26–29 (1960).

  66. 66.

    , & Effect of propionate on lipogenesis in adipose tissue. J. Lipid Res. 8, 682–687 (1967).

  67. 67.

    Effects of indigestible dietary bulk and short chain fatty acids on the tissue weight and epithelial cell proliferation rate of the digestive tract in rats. J. Nutr. Sci. Vitaminol. (Tokyo) 32, 355–362 (1986).

  68. 68.

    et al. Effects of dietary propionate on hepatic glucose production, whole-body glucose utilization, carbohydrate and lipid metabolism in normal rats. Br. J. Nutr. 73, 241–251 (1995).

  69. 69.

    , , & Role of acetate in the reduction of plasma free fatty acids produced by ethanol in man. J. Lipid Res. 9, 509–512 (1968).

  70. 70.

    & Studies on adipose tissue from obese patients with or without diabetes mellitus. Acta Med. Scand. 179, 221–227 (1966).

  71. 71.

    , , & Propionate lowers blood glucose and alters lipid metabolism in healthy subjects. Am. J. Clin. Nutr. 54, 860–865 (1991).

  72. 72.

    , , , & Effect of rectal infusion of short chain fatty acids in human subjects. Am. J. Gastroenterol. 84, 1027–1033 (1989).

  73. 73.

    , , , & Molecular ecological analysis of the gastrointestinal microbiota: a review. J. Nutr. 134, 465–472 (2004).

  74. 74.

    , & Profiling of complex microbial populations by denaturing gradient gel electrophoresis analysis of polymerase chain reaction-amplified genes coding for 16S rRNA. Appl. Environ. Microbiol. 59, 695–700 (1993).

  75. 75.

    The gut microbiota and obesity: from correlation to causality. Nat. Rev. Microbiol. 11, 639–647 (2013).

  76. 76.

    , , & Insights into the role of the microbiome in obesity and type 2 diabetes. Diabetes Care 38, 159–165 (2015).

  77. 77.

    et al. A core gut microbiome in obese and lean twins. Nature 457, 480–484 (2008).

  78. 78.

    , & Fish oil combined with SCFA synergistically prevent tissue accumulation of NEFA during weight loss in obese mice. Br. J. Nutr. 106, 1449–1456 (2011).

  79. 79.

    et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341, 1241214 (2013).

  80. 80.

    et al. Impact of dietary fiber intake on glycemic control, cardiovascular risk factors and chronic kidney disease in Japanese patients with type 2 diabetes mellitus: the Fukuoka Diabetes Registry. Nutr. J. 12, 159 (2013).

  81. 81.

    , , & Effect of polydextrose and soluble maize fibre on energy metabolism, metabolic profile and appetite control in overweight men and women. Br. J. Nutr. 111, 111–121 (2014).

  82. 82.

    et al. Decreasing cardiovascular risk factors in obese individuals using a combination of PGX® meal replacements and PGX® granules in a 12-week clinical weight modification program. J. Complement. Integr. Med. 10, 135–142 (2013).

  83. 83.

    et al. Improvement effect of resistant maltodextrin in humans with metabolic syndrome by continuous administration. J. Nutr. Sci. Vitaminol. 58, 423–430 (2012).

  84. 84.

    et al. Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am. J. Clin. Nutr. 90, 1236–1243 (2009).

  85. 85.

    , , & Oligofructose promotes satiety in healthy human: a pilot study. Eur. J. Clin. Nutr. 60, 567–572 (2006).

  86. 86.

    , , & A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults. J. Nutr. 143, 324–331 (2013).

  87. 87.

    et al. The impact of oligofructose on stimulation of gut hormones, appetite regulation and adiposity. Obesity 22, 1430–1438 (2014).

  88. 88.

    et al. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 62, 1112–1121 (2013).

  89. 89.

    & Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am. J. Clin. Nutr. 89, 1751–1759 (2009).

  90. 90.

    , & Clinical significance of colonic fermentation. Am. J. Gastroenterol. 85, 1307–1312 (1990).

  91. 91.

    , , , & Inulin propionate ester increases satiety and decreases appetite but does not affect gastric emptying in healthy humans. Proc. Nutr. Soc. 73, E21 (2014).

  92. 92.

    et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut .

  93. 93.

    , , , & Vinegar intake reduces body weight, body fat mass, and serum triglyceride levels in obese Japanese subjects. Biosci. Biotechnol. Biochem. 73, 1837–1843 (2009).

  94. 94.

    et al. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am. J. Physiol. Endocrinol. Metab. 290, E550–E559 (2006).

  95. 95.

    & Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology 133, 233–240 (1993).

  96. 96.

    & Gut hormones and appetite control: a focus on PYY and GLP-1 as therapeutic targets in obesity. Gut Liver 6, 10–20 (2012).

  97. 97.

    , , , & Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut 28, 166–170 (1987).

  98. 98.

    & Gut hormones and the regulation of energy homeostasis. Nature 444, 854–859 (2006).

  99. 99.

    et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am. J. Physiol. 277, R910–R916 (1999).

  100. 100.

    , , , & GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig. Dis. Sci. 34, 703–708 (1989).

  101. 101.

    et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61, 364–371 (2012).

  102. 102.

    et al. The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents. Int. J. Obes. 39, 424–429 (2014).

  103. 103.

    et al. A human cellular model for studying the regulation of glucagon-like peptide-1 secretion. Endocrinology 142, 4522–4528 (2001).

  104. 104.

    et al. Short chain fatty acids stimulate the release of gut hormone peptide YY from human primary enteroendocrine L cells. Proc. Physiol. Soc. 27, PC331 (2012).

  105. 105.

    et al. Short-chain fatty acid receptor, GPR43, is expressed by enteroendocrine cells and mucosal mast cells in rat intestine. Cell Tissue Res. 324, 353–360 (2006).

  106. 106.

    , & Inulin-type fructans modulate gastrointestinal peptides involved in appetite regulation (glucagon-like peptide-1 and ghrelin) in rats. Br. J. Nutr. 92, 521–526 (2004).

  107. 107.

    et al. Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents. Am. J. Physiol. Endocrinol. Metab. 295, E1160–E1166 (2008).

  108. 108.

    , , & Oligofructose promotes satiety in rats fed a high-fat diet: involvement of glucagon-like peptide-1. Obesity Res. 13, 1000–1007 (2005).

  109. 109.

    et al. Peptide YY and proglucagon mRNA expression patterns and regulation in the gut. Obesity 14, 683–689 (2006).

  110. 110.

    , , & Dietary non-digestible carbohydrates promote L-cell differentiation in the proximal colon of rats. Br. J. Nutr. 98, 32–37 (2007).

  111. 111.

    et al. Gut hormone release and appetite regulation in healthy non-obese participants following oligofructose intake. A dose-escalation study. Appetite 66, 44–53 (2013).

  112. 112.

    et al. Microbial modulation of energy availability in the colon regulates intestinal transit. Cell Host Microbe 14, 582–590 (2013).

  113. 113.

    et al. Increased brain uptake and oxidation of acetate in heavy drinkers. J. Clin. Invest. 123, 1605–1614 (2013).

  114. 114.

    et al. Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41. Proc. Natl Acad. Sci. USA 101, 1045–1050 (2004).

  115. 115.

    et al. Inverse regulation of leptin mRNA expression by short-and long-chain fatty acids in cultured bovine adipocytes. Domest. Anim. Endocrinol. 33, 400–409 (2007).

  116. 116.

    & Coordinate regulation of ovine adipose tissue gene expression by propionate. J. Anim. Sci. 80, 2840–2849 (2002).

  117. 117.

    , , & Abnormal regulation of the leptin gene in the pathogenesis of obesity. Proc. Natl Acad. Sci. USA 95, 11852–11857 (1998).

  118. 118.

    et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat. Med. 1, 1155–1161 (1995).

  119. 119.

    et al. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat. Med. 1, 1311–1314 (1995).

  120. 120.

    , , & Acetic acid upregulates the expression of genes for fatty acid oxidation enzymes in liver to suppress body fat accumulation. J. Agric. Food Chem. 57, 5982–5986 (2009).

  121. 121.

    et al. Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proc. Natl Acad. Sci. USA 108, 8030–8035 (2011).

  122. 122.

    & Intestinal glucose metabolism revisited. Diabetes Res. Clin. Pract. 105, 295–301 (2014).

  123. 123.

    et al. Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids. Endocrinology 149, 4519–4526 (2008).

  124. 124.

    , & Sodium acetate decreases phosphorylation of hormone sensitive lipase in isoproterenol-stimulated 3T3-L1 mature adipocytes. Adipocyte 3, 121–125 (2014).

  125. 125.

    , & Butyrate and other short-chain fatty acids increase the rate of lipolysis in 3T3-L1 adipocytes. PeerJ 2, e611 (2013).

  126. 126.

    et al. Acetate and propionate short chain fatty acids stimulate adipogenesis via GPCR43. Endocrinology 146, 5092–5099 (2005).

  127. 127.

    et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat. Commun. 4, 1829 (2013).

  128. 128.

    , & Regulation of energy homeostasis by GPR41. Front. Endocrinol. (Laussane) 5, 81 (2014).

  129. 129.

    et al. Roles of GPR41 and GPR43 in leptin secretory responses of murine adipocytes to short chain fatty acids. FEBS Lett. 584, 2381–2386 (2010).

  130. 130.

    et al. Effect of short chain fatty acids on the expression of free fatty acid receptor 2 (Ffar2), Ffar3 and early-stage adipogenesis. Nutr. Diabetes 4, e128 (2014).

  131. 131.

    , & Lipoprotein lipase genetics, lipid uptake, and regulation. J. Lipid Res. 43, 1997–2006 (2002).

  132. 132.

    et al. Bacterial monocultures, propionate, butyrate and H2O2 modulate the expression, secretion and structure of the fasting induced adipose factor in gut epithelial cell lines. Environ. Microbiol. 13, 1778–1789 (2011).

  133. 133.

    , , , & Redundant control of adipogenesis by histone deacetylases 1 and 2. J. Biol. Chem. 285, 14663–14670 (2010).

  134. 134.

    , & Short-chain fatty acids enhance adipocyte differentiation in the stromal vascular fraction of porcine adipose tissue. J. Nutr. 144, 1887–1895 (2014).

  135. 135.

    et al. Inulin-type fructans with prebiotic properties counteract GPR43 overexpression and PPARγ-related adipogenesis in the white adipose tissue of high-fat diet-fed mice. J. Nutr. Biochem. 22, 712–722 (2011).

  136. 136.

    et al. Evaluation of the relationship between GPR43 and adiposity in human. Nutr. Metab. 10, 11 (2013).

  137. 137.

    The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol. Behav. 94, 206–218 (2008).

  138. 138.

    & Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 6, 772–783 (2006).

  139. 139.

    et al. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler. Thromb. Vasc. Biol. 28, 1654–1659 (2008).

  140. 140.

    & Control of inflammation by integration of environmental cues by regulatory T cells. J. Clin. Invest. 123, 939–944 (2013).

  141. 141.

    et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat. Med. 15, 914–920 (2009).

  142. 142.

    et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 108, 2460–2466 (2003).

  143. 143.

    et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341, 569–573 (2013).

  144. 144.

    et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504, 446–450 (2013).

  145. 145.

    et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504, 451–455 (2013).

  146. 146.

    , & Effect of short-chain fatty acids on paracellular permeability in Caco-2 intestinal epithelium model. Am. J. Physiol. 272, G705–G712 (1997).

  147. 147.

    et al. Differential modulation of enterocyte-like Caco-2 cells after exposure to short-chain fatty acids. Food Addit. Contam. 20, 427–437 (2003).

  148. 148.

    , & Physiological concentrations of short-chain fatty acids immediately suppress colonic epithelial permeability. Br. J. Nutr. 100, 297–305 (2008).

  149. 149.

    , , , & Short-chain fatty acids activate AMP-activated protein kinase and ameliorate ethanol-induced intestinal barrier dysfunction in Caco-2 cell monolayers. J. Nutr. 143, 1872–1881 (2013).

  150. 150.

    et al. Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat. Commun. 6, 6734 (2015).

  151. 151.

    et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50, 2374–2383 (2007).

  152. 152.

    et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761–1772 (2007).

  153. 153.

    et al. Experimental endotoxemia induces adipose inflammation and insulin resistance in humans. Diabetes 59, 172–181 (2010).

  154. 154.

    et al. Immune cell toll-like receptor 4 mediates the development of obesity-and endotoxemia-associated adipose tissue fibrosis. Cell Rep. 7, 1116–1129 (2014).

  155. 155.

    et al. The endocannabinoid system links gut microbiota to adipogenesis. Mol. Syst. Biol. 6, 392 (2010).

  156. 156.

    , , & Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J. Gastroenterol. 13, 2826–2832 (2007).

  157. 157.

    et al. Short-chain fatty acids suppress lipopolysaccharide-induced production of nitric oxide and proinflammatory cytokines through inhibition of NF-κB pathway in RAW264.7 cells. Inflammation 35, 1676–1684 (2012).

  158. 158.

    et al. Short-chain fatty acids act as antiinflammatory mediators by regulating prostaglandin E2 and cytokines. World J. Gastroenterol. 15, 5549–5557 (2009).

  159. 159.

    et al. Butyrate attenuates inflammation and lipolysis generated by the interaction of adipocytes and macrophages. J. Atheroscler. Thromb. 20, 425–442 (2013).

  160. 160.

    et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 7, 45–56 (2008).

  161. 161.

    , & Metabolic flexibility in the development of insulin resistance and type 2 diabetes: effects of lifestyle. Obes. Rev. 10, 178–193 (2009).

  162. 162.

    et al. Effects of acetate on lipid metabolism in muscles and adipose tissues of type 2 diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Biosci. Biotechnol. Biochem. 73, 570–576 (2009).

  163. 163.

    et al. Acetic acid feeding enhances glycogen repletion in liver and skeletal muscle of rats. J. Nutr. 131, 1973–1977 (2001).

  164. 164.

    , & Molecular cloning and tissue expression of a novel orphan G protein-coupled receptor from rat lung. Biochem. Biophys. Res. Comm. 234, 190–193 (1997).

  165. 165.

    et al. Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide–dependent mechanism. Diabetes 61, 888–896 (2012).

  166. 166.

    et al. Short-chain fatty acids modify colonic motility through nerves and polypeptide YY release in the rat. Am. J. Physiol. 275, G1415–G1422 (1998).

  167. 167.

    et al. Roles of short-chain fatty acids receptors, GPR41 and GPR43 on colonic functions. J. Physiol. Pharmacol. 59, 251–262 (2008).

  168. 168.

    et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc. Natl Acad. Sci. USA 105, 16767–16772 (2008).

  169. 169.

    et al. Gut-derived short-chain fatty acids are vividly assimilated into host carbohydrates and lipids. Am. J. Physiol. 305, G900–G910 (2013).

  170. 170.

    et al. Effect of propionate on fatty acid and cholesterol synthesis and on acetate metabolism in isolated rat hepatocytes. Br. J. Nutr. 74, 209–219 (1995).

  171. 171.

    & Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem. Soc. Trans. 30, 1064–1070 (2002).

  172. 172.

    , & AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab. 9, 407–416 (2009).

  173. 173.

    et al. Acetic acid activates the AMP-activated protein kinase signaling pathway to regulate lipid metabolism in bovine hepatocytes. PLoS ONE 8, e67880 (2013).

  174. 174.

    et al. Improvement of obesity and glucose tolerance by acetate in type 2 diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Biosci. Biotechnol. Biochem. 71, 1236–1243 (2007).

  175. 175.

    , , , & Acetic acid activates hepatic AMPK and reduces hyperglycemia in diabetic KK-A(y) mice. Biochem. Biophys. Res. Comm. 344, 597–604 (2006).

  176. 176.

    , , , & Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis. PLoS ONE 8, e63388 (2013).

  177. 177.

    , & Interaction between colonic acetate and propionate in humans. Am. J. Clin. Nutr. 53, 681–687 (1991).

  178. 178.

    et al. Effect of acetate and propionate on fasting hepatic glucose production in humans. Eur. J. Clin. Nutr. 49, 484–491 (1995).

  179. 179.

    , & Intravenous acetate elicits a greater free fatty acid rebound in normal than hyperinsulinaemic humans. Eur. J. Clin. Nutr. 66, 1029–1034 (2012).

  180. 180.

    , & Effects of dietary propionate on carbohydrate and lipid metabolism in healthy volunteers. Am. J. Gastroenterol. 85, 549–553 (1990).

Download references

Acknowledgements

Research in the authors' laboratory is funded by TI Food and Nutrition, a public–private partnership on precompetitive research in food and nutrition.

Author information

Affiliations

  1. Department of Human Biology, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, Universiteitssingel 50, 6229 ER, Maastricht, PO Box 616, 6200 MD, Maastricht, Netherlands.

    • Emanuel E. Canfora
    • , Johan W. Jocken
    •  & Ellen E. Blaak

Authors

  1. Search for Emanuel E. Canfora in:

  2. Search for Johan W. Jocken in:

  3. Search for Ellen E. Blaak in:

Contributions

All authors researched the data for the article, discussed the content, wrote, edited and approved the manuscript before submission.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Ellen E. Blaak.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrendo.2015.128

Further reading